Cumberland Pharmaceuticals has launched Caldolor, an intravenous formulation of ibuprofen, designed primarily for use in the hospitals.
The company said, Caldolor is an injectable product for the treatment of pain and fever, and is available in both 400mg and 800mg. Cumberland received FDA’s marketing approval for Caldolor in June 2009.
Mr Kazimi, CEO of Cumberland, said: “We are pleased to introduce Caldolor ahead of schedule, offering a new level of patient care as ibuprofen advances to IV. We have worked diligently over the past year to prepare for the introduction of Caldolor to physicians and patients as the only injectable product available in the United States for reduction of fever, and as an important alternative for single-agent and multi-modal pain management.”
Dr Paul White, professor and holder of the McDermott Distinguished Chair of Anesthesiology & Pain Management at the University of Texas Southwestern Medical Center at Dallas and visiting scientist at Cedars Sinai Medical Center in Los Angeles, said: “The introduction of IV ibuprofen (Caldolor) should allow anesthesiologists to achieve improved pain control with less opioid analgesic medication, thereby improving patient satisfaction. The use of IV ibuprofen can help reduce opioid-related side effects, and Caldolor is the first IV analgesic with antipyretic and anti-inflammatory properties.”